A top U.S. senator is pressing for federal authorities to disclose the outcomes of a recent investigation into the dialysis sector which has been criticized for its dualistic dominance over critical kidney care, said to compromise the integrity of treatments that are pivotal to patient survival.
The sector’s dynamics caught wider public attention through a CBS News investigative report, revealing that two predominant companies, Fresenius and DaVita, collectively control about 75% of the nearly 5,600 dialysis clinics across the United States. This consolidation has raised significant concerns about the potential abuse of market power and subsequent negative impacts on patient care. Senator Richard Blumenthal, a Democrat from Connecticut, expressed his concerns to CBS News, highlighting the urgent need for governmental intervention.
Senator Blumenthal pointed out that the government appears to be at a leverage disadvantage against these colossal providers responsible for the vast majority of the nation’s dialysis services. He urged the federal bodies to employ stronger assertiveness, including the use of antitrust authorities to rectify the situation. The Federal Trade Commission (FTC), responsible for regulating anti-competitive behavior, is under scrutiny for its handling of an ongoing investigation into whether the dominance of these firms in the market adversely impacts the quality of care, but details of their findings remain undisclosed.
Blumenthal emphasized the necessity for the FTC to take decisive, robust enforcement actions to correct any identified issues and protect patients, including vulnerable groups like veterans, from possible misconduct by these large corporations. An alarming number of Americans, approximately 500,000, rely on dialysis treatments as they await possible kidney transplants. For those grappling with end-stage kidney disease, dialysis clinics serve as crucial lifelines, offering the essential service of blood filtration.
There is growing concern among critics such as Tom Mueller, author of “How to Make a Killing: Blood, Death and Dollars in American Medicine,” who argues that these clinics—governed by profit motives rather than patient care—fail to provide necessary tailored treatments. Mueller’s insights resonate with findings from economist Ryan McDevitt of Duke University, who pointed out that the dialysis sector is among the most concentrated healthcare segments in the U.S., reflecting a 30-year trend towards a duopolistic market structure.
In defense, both Fresenius and DaVita insist that their operational practices and patient care quality remain exemplary. They reject claims that Medicare’s reimbursement limitations per patient may encourage practices like overbooking sessions to enhance profitability. On record, DaVita and Fresenius collectively reported an astounding $33.7 billion in revenue last year alone, raising questions about the correlation between high revenues and the quality of patient care.
Research spearheaded by McDevitt underscores some startling statistics; he noted a discernible decline in the performance indices of clinics once they come under the control of these giants. Key metrics like patient survival rates, hospitalization rates, and infection rates have all seen deterioration post-acquisition by either DaVita or Fresenius.
From a regulatory perspective, routine health inspections by the Center for Medicare and Medicaid Services (CMS) have unearthed over 115,000 deficiencies across U.S dialysis centers since 2013. These deficiencies span issues like poor hand hygiene, unsanitary conditions during IV medication handling, and inadequate training—a fact that does not align well with the companies’ public assertions of high-quality care provision.
Fresenius asserts that a significant percentage of their centers achieved three stars or higher in Medicare’s five-star rating system—a claim intended to affirm their commitment to high standards of care. Similarly, DaVita maintains that any cited problems within its facilities are exceptions and unreflective of their general care standards, emphasizing their responsiveness to resolving issues as they arise.
Senator Blumenthal’s concerns extend particularly to veterans, some 40,000 of whom depend on dialysis while awaiting kidney transplants. In his communication to FTC Chairman Andrew Ferguson, Blumenthal has pressed for action against what he describes as predatory, monopolistic practices within the dialysis industry, urging for a thorough and impactful FTC investigation.
As these developments unfold, Fresenius has acknowledged its engagement with the FTC investigation, committing to full cooperation, whereas DaVita and the FTC had not provided comments at the time of the reports.
The graveness of the situation, characterized by high market concentration and alleged neglect of patient welfare in favor of profitability, underscores a critical healthcare and regulatory challenge that demands immediate and decisive action to ensure that patient care remains the uncompromised priority in the dialysis industry. As debates and investigations continue, thousands of lives hang in the balance, reliant on the effective resolution of these issues to ensure they receive the care they critically need.
